All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.

  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-05-18T16:24:01.000Z

iwCLL 2017 | Venetoclax plus rituximab is highly active in patients with relapsed/refractory CLL/SLL

Bookmark this article

During iwCLL, on 15th May 2017, the “Additional Therapies for the Relapsed/Refractory CLL Patient” session took place and was co-chaired by Michael Keating (MD Anderson Cancer Center) and Jacqueline Barrientos (The Feinstein Institute for Medical Research).

During this session, Danielle Brander, MD, from the Duke Cancer Institute, Durham, North Carolina, USA, gave a talk titled “Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab.”

Adverse events were graded using the NCI CTCAE v4.0. The iwCLL 2008 criteria was used to evaluate responses including CT or MRI imaging (at end of combination therapy i.e. month 7); CT scans were undertaken every 3–6 months thereafter for all patients. The bone marrow was assessed for MRD using ≥4 color flow cytometry in local laboratories (minimum sensitivity: 0.01%).

  • Best objective response:
    • ORR = 86%; CR/CRi = 51%; nPR/PR = 35%
    • SD = 8%
    • PD = 4%
    • Non-evaluable (1 patient due to fatal TLS) = 2%
  • All patients experienced AEs; the most common were upper respiratory tract infection, neutropenia, and mil GI issues
  • Grade 3–4 AEs occurred in 37 patients (76%); the most common were neutropenia (53%), thrombocytopenia (16%), and anemia (14%)

*TLS, n=1; worsening of peripheral neuropathy, n=1

 

All Patients

Enrolled, n

49

Median (range) time on study, months

38 (<1–53)

Active patients, n

28

Median (range) time on venetoclax, months

40 (28–53)

Discontinuation due to CLL progression, n

7

Discontinuation due to Richter’s transformation, n

5

Other reasons for discontinuation, n

5

AE related to venetoclax

2*

AE considered not related to therapy

1

Withdrew consent

2

Elected to stop venetoclax after response per protocol, n

16

  • Median time to CLL progression (n=7): 28 months (range, 12–50)
  • Median time to Richter’s transformation (n=5): 5 months (range, 1–9)
  • Time on therapy before discontinuation varied according to the protocol version active:
    • Amendment 1 (May–Sept 2012): patients discontinue treatment after achieving CR/CRi
    • Amendments 2 & 3 (Sept 2012–May 2015): patients who achieved CR/CRi and marrow MRD-negativity could discontinue therapy
    • Amendment 4 (May 2015 onward): patients who achieved marrow MRD-negativity (CR/CRi or PR) could discontinue therapy
  • Re-initiation of venetoclax and followed by rituximab was permitted if patients experienced disease progression, as determined by iwCLL criteria

  • Before discontinuations, median time on therapy was 16 months (range, 5–38)
  • After a median of 20 months (range, 6–40), 10/12 active patients remain progression-free off therapy
  • The demographics and disease characteristics of the 16 patients who chose to discontinue therapy were similar to the total study population
  • 3 patients with del(17p) and 1 patient with mutant TP53 achieved MRD-negativity and were progression-free at study discontinuation or remain progression-free off venetoclax

Danielle Brander summarized her talk with a concise conclusion slide:

  1. Brander D. Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab. XVII International Workshop on Chronic Lymphocytic Leukemia; 2017 May 12–15; New York, USA.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox